Media stories about SurModics (NASDAQ:SRDX) have been trending somewhat positive this week, AlphaOne Sentiment reports. AlphaOne, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SurModics earned a daily sentiment score of 0.04 on AlphaOne’s scale. AlphaOne also gave news coverage about the company an impact score of 91 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the near future.
Separately, Zacks Investment Research upgraded shares of SurModics from a “sell” rating to a “hold” rating in a research report on Monday, January 23rd.
SurModics (NASDAQ:SRDX) opened at 22.70 on Friday. The firm’s 50-day moving average is $23.37 and its 200-day moving average is $24.48. SurModics has a 52-week low of $21.56 and a 52-week high of $30.75. The company has a market cap of $301.37 million, a PE ratio of 32.06 and a beta of 1.03.
SurModics (NASDAQ:SRDX) last posted its earnings results on Thursday, April 27th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by $0.02. SurModics had a net margin of 13.46% and a return on equity of 13.14%. The company had revenue of $17.50 million during the quarter, compared to analyst estimates of $16.21 million. During the same quarter last year, the business posted $0.20 EPS. SurModics’s quarterly revenue was up 4.8% compared to the same quarter last year. On average, equities research analysts anticipate that SurModics will post $0.25 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/05/20/somewhat-positive-media-coverage-extremely-likely-to-affect-surmodics-srdx-share-price-updated-updated.html.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.